Further studies are warranted to elucidate the mechanism of action for tumor growth inhibition in FGFR1-overexpressing HCC PDX models, and to confirm the genomic correlation of the drug sensitivity with overexpression of FGFR1 gene. The gene discussed is FGFR1; the disease is hepatocellular carcinoma.